IUPAC: 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one · C₁₅H₁₀ClN₃O₃ · MW 315.72 g/mol · CAS 1622-61-3 · ATC N03AE01 · ChEMBL452
Clonazepam (Klonopin). A high-potency nitrobenzodiazepine — Roche's Ro 5-4023, approved 1975 — sharing the nitro-aromatic scaffold of nitrazepam and flunitrazepam rather than diazepam's chloro group. A positive allosteric modulator of the GABAA receptor at the benzodiazepine site, with sub-nanomolar affinity and a long half-life. Anticonvulsant · panic-disorder anxiolytic · myoclonus / movement-disorder agent. Trade/context names: Klonopin, Rivotril, Ravotril, "K-pins," "clonnies."
Clonazepam does not open the chloride channel by itself. Like every classical benzodiazepine it is a positive allosteric modulator (PAM) binding an extracellular pocket at the α+/γ2− subunit interface of the pentameric GABAA receptor — the "benzodiazepine site," structurally homologous to the two orthosteric GABA sites at the β+/α− interfaces. When GABA is present, clonazepam raises the receptor's affinity for it and increases the frequency of channel openings. What separates clonazepam from diazepam is not the mechanism but the numbers: its 7-nitro group and 2′-chlorophenyl substituent give it sub-nanomolar affinity (Ki ≈ 0.85 nM, roughly an order of magnitude tighter than diazepam) and correspondingly high clinical potency — therapeutic doses are 0.5–2 mg, not 5–10 mg. Benzodiazepines increase opening frequency; barbiturates increase opening duration. That single difference is why isolated benzodiazepine overdose has a ceiling — and why the ceiling evaporates the moment a second CNS depressant is added (see §04).
GABAA is a ligand-gated anion channel. GABA binding at the two β+/α− sites opens the pore; Cl⁻ (and HCO₃⁻) flows down its electrochemical gradient, hyperpolarizing the neuron and raising firing threshold. Clonazepam adds nothing without GABA — it is pure gain, not a switch.
The conserved α-subunit His-101 (α1 numbering) anchors high-affinity benzodiazepine binding. α4 and α6 carry an arginine there instead, rendering those subtypes "diazepam-insensitive" (µM affinity). Clonazepam, like diazepam, is essentially inactive at α4/α6-containing receptors.
α1βγ2 receptors (~60% of brain GABAA) mediate sedation, anterograde amnesia and much of the anticonvulsant and reinforcing action. Clonazepam's high α1 potentiation underlies both its potent seizure suppression and its abuse-related effect.
α2- and α3-containing receptors (limbic system, spinal cord) carry the anxiolytic and myorelaxant effects that make clonazepam useful in panic disorder. Clonazepam is non-selective — it hits α1, α2, α3 and α5 with comparable sub-nM affinity.
α5βγ2 receptors concentrate in the hippocampus and shape learning and memory; clonazepam's α5 potentiation contributes to its amnestic and cognitive-blunting profile — a common complaint on chronic dosing.
By raising the seizure threshold across cortical and limbic circuits, clonazepam suppresses absence, myoclonic and atonic seizures (Lennox-Gastaut) and terminates status epilepticus. Anticonvulsant tolerance, however, limits its role as chronic monotherapy.
Because the effect is use-dependent on ambient GABA, benzodiazepines have a self-limiting envelope in isolation: they can only amplify inhibition where GABA is already being released. Barbiturates, ethanol at high concentration, and — critically — the additive load of an opioid on the same brainstem respiratory circuitry remove that ceiling.
Clonazepam is well absorbed orally (bioavailability ~90%) with a peak at 1–4 h, and it is highly lipophilic, crossing the blood–brain barrier readily. Its defining PK feature is a long elimination half-life of roughly 30–40 h — but, unlike diazepam, clonazepam produces no pharmacologically active metabolites. It is a single long-lived benzodiazepine, not a slow-release cocktail. That combination — long half-life, clean metabolism — is exactly why clonazepam is often preferred over alprazolam for panic disorder: alprazolam's short half-life (~11 h) produces sharp inter-dose troughs, clock-watching rebound anxiety, and abrupt "wearing-off" that drives frequent redosing and reinforces dependence. Clonazepam's slow decline delivers a flatter plasma curve and smoother coverage across the day. The trade-off is accumulation: with a ~35 h half-life, steady state and full washout each take about a week.
Metabolism cascade: Clonazepam's 7-nitro group is reduced (hepatic nitroreduction, CYP3A4-linked) to 7-amino-clonazepam, which is pharmacologically inactive at the BZD site. 7-amino-clonazepam is then N-acetylated by NAT2 to 7-acetamido-clonazepam and cleared renally as conjugates. No step regenerates an active benzodiazepine — the reason clonazepam lacks diazepam's self-perpetuating metabolite chain.
7-amino-clonazepam is the workhorse of forensic and urine testing — it is the dominant urinary marker, since clonazepam itself is almost entirely metabolized. Because clearance runs through CYP3A4, CYP3A4 inhibitors — azole antifungals, macrolides, ritonavir, grapefruit juice — raise clonazepam exposure, while strong inducers (carbamazepine, phenytoin, rifampicin) lower it and can precipitate breakthrough seizures. NAT2 acetylator status (fast vs slow, a classic pharmacogenetic polymorphism) modulates the downstream acetylation step. As with any long-half-life benzodiazepine, dose changes take about a week to reach a new steady state — stacking doses "because it isn't working yet" is a common route to unintentional over-sedation.
Clonazepam earns its place in two clinics at once. As an anticonvulsant it suppresses absence, myoclonic and atonic seizures and aborts status epilepticus; as a high-potency, long-acting anxiolytic it is a mainstay of panic disorder and is used off-label for restless legs, REM-sleep behavior disorder, akathisia and other movement disorders. Subjectively it delivers anxiolysis, muscle relaxation, sedation and anterograde amnesia, with mild euphoria and disinhibition underwriting its recreational value (largely α1-mediated). But the clinically decisive story is adaptation: the GABAergic system does not tolerate sustained potentiation without remodeling — and that remodeling is what produces tolerance, dependence and a withdrawal syndrome that can kill.
Clonazepam's anticonvulsant efficacy frequently wanes over weeks to months of continuous use as GABAA receptors undergo subunit trafficking and uncoupling of the BZD site from the GABA site. This tolerance is precisely why benzodiazepines are second-line for chronic epilepsy and are reserved for rescue and acute control — the same dose delivers progressively less protection.
To offset chronic inhibition, the CNS down-regulates GABAergic tone and up-regulates glutamatergic (NMDA) drive. As long as clonazepam is present the system is balanced; remove it and the compensations are unmasked — the brain is now wired for hyperexcitability. Dependence can develop within weeks of daily therapeutic use; it is a physiological adaptation, not a character flaw.
Abrupt cessation after sustained use produces rebound anxiety, panic and insomnia, tremor, sweating, perceptual disturbance, and — in severe cases — generalized tonic-clonic seizures, psychosis and delirium, mechanistically analogous to alcohol withdrawal. A cruel irony for an anticonvulsant: stopping it too fast can cause seizures in someone who never had epilepsy. Because of the long half-life, onset can be delayed several days after the last dose, masking causation. A subset experience protracted withdrawal lasting months.
The evidence-based response is a gradual dose taper, often over months. Clonazepam's own long half-life makes it a relatively smooth taper agent, and shorter-acting benzodiazepines (alprazolam, lorazepam) are sometimes converted to a longer-acting equivalent precisely to flatten the withdrawal gradient (the "Ashton manual" approach). Never stop abruptly after regular use. Taper is a medical procedure, not a test of willpower.
This is the central asymmetry of clonazepam: in isolation it is one of the safer psychoactive drugs ever made — the therapeutic-index margin against fatal respiratory depression is wide — yet it creates a dependence that makes stopping genuinely hazardous, and it becomes lethal the instant it is stacked with another respiratory depressant. The molecule is not the danger. The combination and the discontinuation are.
Evidence-based, non-judgmental. Clonazepam's risks are dominated by two things: what you combine it with, and how you stop it. Both are manageable with accurate information.
| Target (subtype) | Affinity | Rel. | Action |
|---|---|---|---|
|
GABAA · BZD site
[³H]flumazenil displacement (composite)
|
Ki ≈ 0.85 nM
ChEMBL CHEMBL452
|
PAM | |
|
α1β2γ2
GABAA · sedation / anticonvulsant
|
Ki sub-nM
non-selective
|
PAM | |
|
α2 / α3βγ2
GABAA · anxiolytic / anti-panic
|
Ki sub-nM
non-selective
|
PAM | |
|
α5βγ2
GABAA · hippocampal / memory
|
Ki sub-nM
non-selective
|
PAM | |
|
α4 / α6βγ2
GABAA · "diazepam-insensitive"
|
Ki µM-range
Arg at His-101
|
≈ inactive |